

ARTIVION™

**ARTIVION, INC.
BOARD OF DIRECTORS
INNOVATION AND HEALTHCARE COMPLIANCE COMMITTEE CHARTER**

PURPOSE

In order to assist the Board of Directors (the “Board”) of Artivion, Inc. (the “Corporation”) in fulfilling its responsibilities, the purpose of the Innovation and Healthcare Compliance Committee (the “Committee”) shall be to:

- Assist the Board in the general oversight of the Corporation’s ongoing scientific and technological innovation activities and initiatives, including research and development (“R&D”), clinical, regulatory, and intellectual property matters.
- Assist the Board in its oversight of the Corporation’s compliance with healthcare laws and programs, broadly defined to include:
 - the Corporation’s quality systems and regulatory compliance, including the systems in place to identify deviations from the Corporation’s quality systems and regulatory compliance procedures and the Corporation’s efforts to meet its quality and regulatory compliance responsibilities (hereinafter referred to as “Quality Systems and Regulatory Compliance”) and
 - the Corporation’s other healthcare compliance programs, including matters related to compliance with federal healthcare requirements and programs and other non-financial healthcare legal and regulatory requirements (hereinafter referred to as “Healthcare Compliance”).
- Together with the Audit Committee, the Committee shall assist the Board in its oversight of legal and regulatory compliance, including with respect to the Corporation’s use of artificial intelligence based technologies. The Audit Committee shall have sole oversight over matters of financial compliance, and the Committee shall have primary oversight responsibilities as to the Corporation’s Quality Systems and Regulatory Compliance and Healthcare Compliance, as further described in Roles and Responsibilities below.

ORGANIZATION

The Committee shall have a minimum of three members of the Board. At least one member of the Committee shall serve concurrently on the Audit Committee. A majority of the Committee members will meet all applicable independence requirements for non-employee directors under the rules of the New York Stock Exchange (“NYSE”) and the Securities and Exchange Commission (“SEC”), as such requirements are interpreted by the Board in its business judgement. In the event a majority of the members of the Committee do not meet the independence standards set forth above, the Corporate Governance Committee shall immediately recommend to the Board such changes to membership on the Committee that will result in a majority of Committee members meeting the independence requirements of the NYSE, SEC, or other applicable law(s).

ARTIVION™

PROCESS AND PROCEDURES

The Committee shall:

- Be appointed by the full Board, upon the recommendation of the Corporate Governance Committee, subject to annual appointment, and each member shall serve until the earlier of his or her resignation or removal by the Board.
- Meet at least three times annually, in person, telephonically, or digitally (e.g., via webcast) and make available the minutes of all meetings of the Committee to, and review the material matters discussed at each Committee meeting with, the Board.
- Meet jointly at least annually with the Audit Committee, at which the combined committees shall discuss with the full Board and management the Corporation's Enterprise Risk Management assessment and plan, healthcare compliance, including compliance with the Foreign Corrupt Practices Act, and other items of the Corporation's strategic plan directed to legal and regulatory healthcare compliance.
- Meet as necessary with any independent advisors retained by the Committee and with designated members of senior management, including the Corporation's General Counsel and/or Chief Compliance Officer.
- Hold meetings led by a Chair, appointed by the Board, pursuant to an agenda approved by the Chair. In the absence of the Chair, at any meeting of the Committee at which a quorum is present, a majority of the members of the Committee may elect an acting chair of the meeting. The Committee shall have authority to delegate any decisions to a subcommittee of the Committee, consisting of at least two persons. The Chair of the Committee shall have authority to take action on behalf of the Committee subject to ratification by the Committee.
- Have the sole authority to retain, determine the terms of engagement and compensation of, and terminate, any advisors, consultants, and/or experts the Committee deems necessary or appropriate to help it carry out its duties hereunder.
- Submit to the Board annually a budget of its expected expenditures for that year for the Board's review and approval.
- Evaluate annually the performance of the Committee and its members.
- Review and assess the adequacy of this Charter annually and recommend any changes to the Corporate Governance Committee and the Board for approval.

ARTIVION™

ROLES AND RESPONSIBILITIES

On behalf of the Board, the Committee shall among its duties and responsibilities:

Innovation and Strategy

- Assess the Corporation's products and services portfolio, including potentially transformative technologies, and its effect on the Corporation's growth, performance, and competitive position and make recommendations to the Board where appropriate.
- Monitor and review the overall strategy, direction, effectiveness, and competitiveness of the Corporation's R&D and clinical activities, including reviewing the Corporation's R&D and clinical trial pipeline.
- Assist the Board, where appropriate, in staying informed of relevant industry trends and in evaluating the scientific, technological, regulatory, clinical, and intellectual property aspects involved in identifying new markets and potential ventures, licenses, acquisitions, and other similar projects.
- Review the Corporation's response to any identified technological and/or supply chain vulnerabilities involving its products and services.
- Report regularly to the Board on Committee findings and recommendations and any other matters the Committee deems appropriate or the Board requests.

Compliance

- Together with the Audit Committee, the Committee shall assist the Board in its oversight of the Corporation's legal and regulatory compliance, as it relates to compliance with healthcare laws and programs and the Corporation's use of artificial intelligence based technologies. The Audit Committee shall have sole oversight over matters of financial compliance, including financial reporting, internal controls, and financial risk exposure to the Corporation resulting from legal and regulatory healthcare compliance matters, broadly defined. As to all other areas of legal and regulatory healthcare compliance (broadly defined) ("non-financial compliance"), the Committee shall have primary oversight responsibilities.

Quality Systems and Regulatory Compliance

- Oversee the risks associated with the Corporation's Quality Systems and Regulatory Compliance and initiatives by reviewing and discussing with senior management:
 - The adequacy and effectiveness of the Corporation's Quality Systems and Regulatory Compliance and initiatives, and consider recommendations for improvement;
 - Significant: (a) deviations from the Corporation's Quality Systems and Regulatory Compliance; (b) product complaints; (c) field actions, including recalls; (d) corrective and preventative actions; (e) results of Food and Drug Administration ("FDA") inspections and notified body or other international regulatory authority audits; (f) Medical Device

ARTIVION™

or other adverse event reporting; (g) regulatory submissions and registrations; and (h) other relevant matters requested by the Committee;

- Material management documents provided to or received from external quality assurance inspectors, such as the FDA, notified bodies, or other international regulatory authorities;
 - Significant activities undertaken by the Corporation as a result of internal Quality Systems and Regulatory Compliance audits;
 - Reports, or summaries thereof, of third-party consultants retained to evaluate the Corporation's Quality Systems and Regulatory Compliance; and
 - Periodic updates regarding the Corporation's Quality Systems and Regulatory Compliance and quality assurance training and education programs for employees of the Corporation.
- Recommend to the Board such actions as it deems necessary or appropriate to improve the effectiveness of the Corporation's Quality Systems and Regulatory Compliance.

Healthcare Compliance Program

- Oversee, and the risks associated with, (i) the Corporation's Healthcare Compliance program, including the Corporation's Code of Conduct and compliance with U.S. and international healthcare programs and laws and (ii) compliance with all compliance agreements with any governmental authority.
- Conduct, on an annual basis, an evaluation of the Corporation's Healthcare Compliance program.
- Review and discuss with senior management the adequacy and effectiveness of the Corporation's Healthcare Compliance program and consider recommendations for improvement thereof.
- At regularly scheduled meetings discuss with the General Counsel and Chief Compliance Officer the effectiveness of the Corporation's Healthcare Compliance program, including significant compliance-related activities undertaken by the Corporation, the results of significant compliance audits and investigations conducted under the compliance program, and the implementation of actions taken as a result of significant Healthcare Compliance audits and investigations.
- Receive and discuss with senior management significant reports from third parties regarding the Corporation's Healthcare Compliance program.
- Receive and discuss with senior management periodic updates regarding the Corporation's training and education programs for employees of the Corporation that pertain to the Healthcare Compliance program.

ARTIVION™

- Assess the Corporation's Code of Conduct no less frequently than annually and recommend to the Board any revisions thereto. The Committee shall determine, following review with the General Counsel and Chief Compliance Officer, any material waivers to the Code of Conduct involving an officer or non-employee director of the Corporation. The Committee shall advise the Board with respect to any potential conflicts of interest and any material waivers of the Code of Conduct involving an officer or non-employee director of the Corporation.
- Recommend to the Board such actions as it deems necessary or appropriate to improve the effectiveness of the Corporation's Healthcare Compliance program.
- Perform such other functions as may be necessary or appropriate for the performance of its duties.

Nothing in this Charter is intended to preclude or impair the protection provided by Delaware law, including Section 141(e) of the General Corporate Law of the State of Delaware, allowing members of the Committee in discharging their duties to rely on information, opinions, reports, or statements, including financial statements and other financial data, if prepared or presented by the persons identified therein.

August 2026